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VOLUME 47 | NUMBER 10 | OCTOBER 2015 Nature GeNetics A r t i c l e s mutations from >8,200 tumor-normal pairs. We discovered an exceptionally broad, low-density and conserved H3K4me3 epigenetic signature that is explicitly enriched in tumor-suppressor genes but not in oncogenes or housekeeping genes. We also experimentally validated our findings in human primary tumor-normal pairs and cell models.
RESULTS

Exceptionally broad H3K4me3 signature in tumor suppressors
We recently observed that the chromatin immunoprecipitation and sequencing (ChIP-seq) peak for H3K4me3, a well-known active promoter epigenetic mark, can span up to 10 kb with low density from the promoter to the gene body in several well-known tumor suppressors, such as IKZF1 (refs. 17-19) and PTEN 20, 21 in human CD4 + T cells 22 (Fig. 1a) . In contrast, H3K4me3 has sharp ChIP-seq peaks of ~1 kb in length in other active genes, such as the housekeeping genes COPB2 (ref. 23 ) and CWC22 (ref. 23) (Fig. 1a) . This observation motivated us to perform a systematic analysis of the height and width (Fig. 1b) of every H3K4me3 promoter peak. We observed a subset of low-density H3K4me3 peaks that were exceptionally wide (defined as broad peaks hereafter) and another subset of high-density H3K4me3 peaks that were relatively narrow (defined as sharp peaks hereafter) (Fig. 1c) . Interestingly, there was no overlap between the broad and sharp peaks, suggesting potentially distinct mechanisms for these two groups of peaks. To conduct a quantitative comparison of broad and sharp H3K4me3 peaks, we retrieved 500 broad H3K4me3 peaks greater than 4 kb in width, which is fivefold wider than the median width of all peaks, 500 sharp peaks with the top peak heights and 500 random peaks as a control (Fig. 1d) . The broad H3K4me3 peaks had a skewed distribution around the transcription start site (TSS), spanning from approximately −500 bp to +3,500 bp, whereas sharp and control H3K4me3 peaks were enriched in a ~1-kb symmetrical region around the TSS (Fig. 1e) . As expected, the signal density of broad H3K4me3 peaks was lower than that of sharp H3K4me3 peaks but slightly higher than that of control H3K4me3 peaks. A composite plot of H3K4me3 ChIP-seq and input samples indicated that the difference between broad and sharp peaks was not due to variation in the genomic background ( Supplementary Fig. 1 ).
We used Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis to characterize enriched functions for the genes associated with the three groups of H3K4me3 peaks. T cell receptor npg signaling (hsa04660) was explicitly enriched in the group with broad H3K4me3 peaks (q = 1.68 × 10 −10 ) but not in the groups with sharp or control peaks (Fig. 1f) . This observation suggests that broad H3K4me3 peaks might be associated with genes maintaining cell identity. Another interesting term, pathways in cancer (hsa05200), a collection of well-curated signaling networks involved in cancer development, was also uniquely enriched in broad H3K4me3 peaks, with a significant q value of 5.67 × 10 −5 (Fig. 1f) . In contrast, housekeeping genes involved in oxidative phosphorylation (hsa00190) 24 were uniquely enriched in sharp H3K4me3 peaks (Fig. 1f) .
To further confirm the association between broad H3K4me3 peaks and cancer development, we collected the top 500 high-confidence tumor suppressors and oncogenes, defined on the basis of distinct somatic mutational patterns, from the genome sequencing of >8,200 tumor-normal pairs 2 . We also used 500 randomly selected housekeeping genes as a control 23 . We repeated the same enrichment analysis on the different H3K4me3 groups, with 500 peaks in each group, ranking the peaks from wide to narrow, high to low, or randomly (Fig. 1g) . Surprisingly, the H3K4me3 group with the broadest peaks was only enriched in tumor suppressors but not oncogenes or housekeeping genes. The enrichment levels gradually diminished with a decrease in peak width. We further confirmed that this enrichment preference for tumor suppressors was not due to bias in our driver gene collection, as tumor suppressors and oncogenes showed similarly significant enrichment for KEGG pathways in cancer ( Supplementary  Fig. 2 ). In addition, H3K4me3 usually had broader peaks at tumor suppressors than at oncogenes or other genes within the same KEGG pathways (Supplementary Fig. 3) . Therefore, the enrichment of functional pathways, such as T cell receptor signaling ( Fig. 1f and   Supplementary Fig. 3a) , in genes associated with broad H3K4me3 peaks is mainly contributed by tumor suppressors within the same pathway. Finally, broad H3K4me3 peaks, although having low signal intensity (Fig. 1e) , were associated with genes with exceptionally higher levels of expression than those associated with sharp or control H3K4me3 peaks (Fig. 1h,i and Supplementary Fig. 4 ). Taking these data together, we conclude that broad H3K4me3 peaks in CD4 + T cell are strongly and uniquely associated with cell identity genes, tumor suppressors and highly expressed genes.
Broad H3K4me3 is not associated with alternative TSSs
An obvious question is whether broad H3K4me3 peaks imply the use of an alternative TSS and induce cryptic transcription 25 . To address this question, we collected a pool of 244,524 unique TSSs from gene models such as those in the RefSeq, UCSC known gene, Ensembl and GENCODE databases. We observed no difference in TSS density among genes associated with broad, sharp and control H3K4me3 peaks (Supplementary Fig. 5a ). To further confirm this result, we repeated the same analysis using CAGE (cap analysis gene expression) data, that is, direct sequencing of TSSs, in CD4 + T cells, but we still observed little difference among the three groups of H3K4me3 peaks ( Supplementary Fig. 5b ). Taking this evidence together, we conclude that broad H3K4me3 peaks are not associated with alternative TSSs.
Many promoter epigenetic marks coincide with broad H3K4me3
To understand the possible mechanisms underlying broad H3K4me3peaks, we mapped ChIP-seq data for 42 distinct epigenetic marks in CD4 + T cells to the same 3 groups of H3K4me3 peaks. In total, 28 epigenetic marks were enriched around promoters, whereas A r t i c l e s 2 marks showed depletion ( Fig. 2a and Supplementary Fig. 6 ). The remaining 12 marks had weak or complicated patterns and were thus excluded from further analysis (Supplementary Fig. 7 ). Twenty-seven of the 28 promoter-enriched epigenetic marks, with the exception of histone variant H2A.Z, had similarly wide peaks at genes with broad H3K4me3 peaks and similarly sharp peaks at genes with sharp or control H3K4me3 peaks. Spearman correlation analysis also indicated the strong similarity between most of these epigenetic marks and broad H3K4me3 (Supplementary Fig. 8 ). The co-occurrence of broad or sharp epigenetic marks was frequently observed at individual genes. For example, the tumor suppressor IKZF1 was strongly associated with broad peaks of promoter-associated epigenetic marks, whereas the housekeeping gene COPB2 had all sharp peaks (Fig. 2b) . This observation suggests the extension of almost all promoter-associated epigenetic marks on a small group of genes, with H3K4me3 being a suitable surrogate marker.
Broad H3K4me3 indicates increased transcription elongation
Interestingly, at genes with broad H3K4me3 peaks, the RNA polymerase II (Pol II) ChIP-seq signal not only was enriched at the promoter and in the gene body but also showed a clear peak at the 3′ end of the gene (Fig. 3a,  left) . This pattern has been reported to be specific for genes undergoing active transcription elongation 26, 27 . Consistent with this observation, the elongation-associated histone mark dimethylation of histone H3 at lysine 79 (H3K79me2), a mark beneficial to the early phase of productive elongation and strongly correlated with elongation rates 28, 29 , showed strong peaks at genes with broad H3K4me3 peaks (Fig. 3a, right) .
We used a well-established Pol II pausing index (or traveling ratio) to quantify transcriptional elongation. The pausing index is the promoter to gene body ratio of Pol II ChIP-seq density 26, 30 ; thus, a larger pausing index indicates more poised Pol II and less elongation. As expected, the Pol II pausing index showed a strong negative correlation with promoter H3K4me3 peak width (Spearman coefficient = −0.70) in human CD4 + T cells (Fig. 3b) . Furthermore, this strong negative correlation was highly reproducible in 14 additional normal cell types ( Fig. 3b and Supplementary Fig. 9 ). These observations are consistent with an association between broad H3K4me3 peaks and increased transcription elongation.
To gain insights into the cause-and-effect relationship, we measured H3K4me3 levels after manipulating the elongation machinery. The MYC oncogene has been reported to promote release from Pol II pausing and to hence amplify global transcriptional elongation and gene expression in cancers 26, 30 . An interesting question is whether MYC has a similar effect on oncogenes and tumor suppressors. When the MYC expression level was lower (blue curves in Fig. 3c,d ) 30, 31 , the Pol II pausing index increased significantly at genes with sharp and control but not broad H3K4me3 peaks 27 (Fig. 3c) . Accordingly, H3K4me3 peak width also changed significantly at sharp and control H3K4me3 peaks but not at promoters with broad H3K4me3 peaks 28 (Fig. 3d) . We also observed a similar change in H3K4me3 peak width by treating human A549 cells for 1 h with flavopiridol ( Fig. 3e) , a specific inhibitor of positive transcription elongation factor b (P-TEFb) 32 , and performing H3K4me3 MNase ChIP-seq. Taking these data together, we conclude that regulators of transcriptional elongation, such as MYC and P-TEFb, seem to drive H3K4me3 epigenetic domain extension at genes with low baseline levels of elongation but not at genes already undergoing strong elongation, such as tumor-suppressor genes.
Broad H3K4me3 has strong and distinct enhancer activity
Several enhancer-associated marks, such as acetylation of histone H3 at lysine 27 (H3K27ac) and monomethylation of histone H3 at lysine 4 (H3K4me1), also showed strong enrichment at genes with broad H3K4me3 peaks (Fig. 4a,b) . To further test the enhancer association, we collected motif instances for 127 transcription factors across the whole genome 33 and evaluated their enrichment levels at the 3 groups of H3K4me3 peaks. Interestingly, motif occurrence was higher across the entire gene body of genes associated with broad H3K4me3 peaks ( Fig. 4c) . We further analyzed the in vivo binding sites of 119 transcription factors in 72 cell lines on the basis of 411 Encyclopedia of DNA Elements (ENCODE) ChIP-seq data sets 34 . In agreement with the motif result, we observed higher transcription factor binding intensity at genes with broad H3K4me3 peaks (Fig. 4d) .
The strong link to enhancer-associated marks suggests that broad H3K4me3 peaks might be associated with super-enhancers 14 , which are also exceptionally broad. To test this hypothesis, we collected super-enhancers and typical enhancers defined in CD4 + T cells 15 . As expected, on one hand, 231 (39%) genes assigned super-enhancers had strong overlap with genes assigned broad H3K4me3 peaks (Fig. 4e) . Most of the remaining 358 (61%) genes with super-enhancers contained sharp H3K4me3 peaks (Fig. 4f) . On the other hand, 231 (46%) of the top 500 genes assigned broad H3K4me3 peaks had overlap with genes assigned super-enhancers (Fig. 4e,f) . In contrast, genes with sharp or control H3K4me3 peaks had little overlap with genes with super-enhancers (Supplementary Fig. 10 ). Interestingly, tumor suppressors were only enriched (Fig. 4g) in genes assigned broad H3K4me3 peaks lacking super-enhancers (group I in Fig. 4e) , indicating that the tumor-suppressor link is highly specific to broad H3K4me3 peaks. These results were highly reproducible in most of the 61 additional cell or tissue types analyzed ( Supplementary  Fig. 11 ). In contrast, cell identity genes, for example, those involved in T cell signaling, were enriched ( Fig. 4g) in genes with either broad H3K4me3 peaks or super-enhancers (group I, II or III in Fig. 4e ). In summary, broad H3K4me3 is strongly associated with enhancer activity, and its unique functional enrichment for tumor suppressors makes this epigenetic signature distinct from super-enhancers.
Broad H3K4me3 at tumor suppressors is highly conserved
To understand broad H3K4me3 signal beyond CD4 + T cells, we collected 105 ENCODE H3K4me3 ChIP-seq data sets from 43 normal cell types. Altogether, we detected 4,167 non-redundant promoter H3K4me3 peaks wider than 4 kb (Fig. 5a) . We ranked and further divided these H3K4me3 peaks into nine groups (A to I) on the basis of the conservation level of H3K4me3 peak width (percentage of samples with H3K4me3 peaks longer than 4 kb) from high to low. The top group, group A, had high conservation with H3K4me3 peaks wider than 4 kb in more than 50% of the cell types. Embryonic stem cells (ESCs) often had small numbers of broad H3K4me3 peaks ( Fig. 5b and  Supplementary Table 2 ), but they tended to retain the most conserved ones. These conserved broad H3K4me3 peaks might be developed very early in ESCs and maintained in various somatic cell types.
Interestingly, tumor suppressors were only significantly (Fisher's exact test, P < 1 × 10 -5 ) enriched in the top two groups with the most conserved H3K4me3 peaks and quickly became non-enriched in the groups with less conserved peaks (Fig. 5c) . TP53 and PTEN are examples of well-established tumor suppressors with conserved broad H3K4me3 peaks across 105 ENCODE normal H3K4me3 ChIP-seq data sets (Fig. 5d) . In contrast, cell identity genes, such as CD4, showed broad H3K4me3 peaks only in a few specific cell types (Fig. 5e) . These results were highly reproducible in another independent H3K4me3 ChIP-seq data set from the Roadmap Epigenomics Project. The Roadmap data contained 153 H3K4me3 ChIP-seq samples from different normal cell types and tissues, which allowed us to detect 8,143 promoters with H3K4me3 peaks wider than 4 kb ( Supplementary  Fig. 12a ). Similar to in the ENCODE data, only the most conserved broad H3K4me3 peaks derived from Roadmap were enriched in tumor suppressors (Supplementary Fig. 12b) . Furthermore, the majority (75%) of the top 500 genes with the most conserved broad H3K4me3 peaks were present in this group in both ENCODE and Roadmap data (Supplementary Fig. 12c ). The combined ENCODE and Roadmap broad (>4-kb) H3K4me3 peaks are listed in Supplementary Table 3 .
To understand the difference between conserved and cell typespecific broad H3K4me3 peaks, we used KEGG pathway enrichment to compare the broad H3K4me3 peaks derived from CD4 + T cells alone (broad group in Fig. 1c ) with those conserved across 105 ENCODE samples (group A in Fig. 5a ). As expected, the conserved broad 
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H3K4me3 peaks did not have the cell identity genes enriched for cell type-specific peaks but shared the pan-cancer tumor suppressors that are required by many somatic cells, such as those involved in p53 signaling (hsa04115), the cell cycle (hsa04110), pathways in cancer (hsa05200) and various cancer pathways, such as colorectal cancer, leukemia, glioma, prostate cancer, basal cell carcinoma, renal cell carcinoma, melanoma, endometrial cancer and small-cell lung cancer (Fig. 5f) . In contrast, the cell type-specific broad H3K4me3 peaks were enriched in both T cell receptor signaling and pathways in cancer. Taking these data together, the conserved broad H3K4me3 peaks are likely to originate from ESCs and are enriched for a group of pan-cancer tumor suppressors that function in a variety of normal somatic cell types.
H3K4me3 shortening indicates transcription repression
To compare cancer and normal cells, we collected additional H3K4me3 ChIP-seq data from 20 ENCODE cancer cell lines. By pooling ChIPseq data from cancer (n = 63) and normal (n = 105) samples together, we detected a total of 6,104 promoter H3K4me3 peaks wider than 4 kb. Close inspection of this rich data set allowed us to observe that many tumor-suppressor genes, such as KLF6 and SPRY2 (Fig. 6a) , with conserved broad H3K4me3 peaks across normal cells were subject to H3K4me3 peak shortening in cancer cells. These examples motivated us to undertake a systematic comparison of known tumorsuppressor genes that have conserved broad 
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H3K4me3 peaks in either cancer or normal cells ( Fig. 6b-d) . Using a Poisson test P-value cutoff of 1 × 10 −100 and a subtraction cutoff of 500 bp, we defined 50 tumor suppressors with H3K4me3 peak shortening in cancers, 3-fold more than the 17 H3K4me3 peak lengthening events (Supplementary Table 4 ). We also defined 29 stable tumor suppressors with broad H3K4me3 peaks (mean width > 4 kb) in both cancer and normal cells (Supplementary Table 4 ). Through randomly shuffling the cancer and normal labels for the ChIP-seq samples, we repeated the mock comparison 1,000 times and defined 36.2 genes on average with stable broad H3K4me3 peaks but almost no genes with H3K4me3 peak shortening or lengthening. Expanding the cancer-normal comparison to all genes (not limiting to known tumor suppressors) with conserved broad H3K4me3 peaks gave similar results, with 200 genes showing H3K4me3 peak shortening and enrichment in tumor suppressors and 91 genes showing H3K4me3 peak lengthening but no tumor-suppressor enrichment ( Supplementary Fig. 13a-c) . These analyses confirmed the widespread shortening of broad H3K4me3 peaks in cancers. To evaluate changes in expression for genes with broad H3K4me3 peaks, we collected microarray data from ENCODE cancer (n = 79) and normal (n = 157) cell samples. As expected, H3K4me3 peak shortening in cancers correlated with transcription repression, whereas stable broad H3K4me3 peaks correlated with high expression levels in both cancer and normal cells ( Fig. 6d and Supplementary  Fig. 13d) . We also observed similar results through comparison of Jurkat leukemic T cells with normal CD4 + T cells ( Supplementary  Fig. 14) and MCF7 breast cancer cells with normal human mammary epithelial cells (HMECs) (Supplementary Fig. 15 ). As expected, the shortening of broad H3K4me3 peaks was also associated with an increase in the Pol II pausing index (Supplementary Fig. 14c ), suggesting reduced transcription elongation and expression levels. Taking these data together, we conclude that the widespread shortening of broad H3K4me3 peaks is associated with reduced expression of tumor suppressors in cancers.
Widespread shortening of broad H3K4me3 in primary tumors
On the basis of the above pan-cancer analysis in cell lines, we hypothesized that widespread shortening of broad H3K4me3 peaks might also exist in primary human tumors. As we were not able to find any published tumor H3K4me3 ChIP-seq data, we performed H3K4me3
ChIP-seq assays using matched tumor-normal pairs from lung ( Fig. 7) and liver (Supplementary Fig. 16 ). Of note, matched tumor-normal pairs from the same patients allow unbiased and efficient analysis of H3K4me3 peak width. As observed in cell lines, broad H3K4me3 peaks in normal lung tissues were associated with tumor suppressors (Fig. 7a) , and shortening of broad H3K4me3 peaks was frequently observed at established tumor suppressors, such as GPX3 (ref. 35) and PLK2 (refs. 36-38) (Fig. 7b) . In total, we identified 209, 108 and 248 genes with shortened, lengthened and stable broad H3K4me3 peaks in lung tumors relative to normal lung tissues, respectively (Fig. 7c) . As expected, the shortening of broad H3K4me3 peaks was associated with gene repression (Fig. 7d) . We also observed similar results through comparison of liver tumors and matched normal tissues (Supplementary Fig. 16 ). Together, these patient sample data generalize our results from cell lines and suggest the potential clinical significance of our finding that widespread shortening of broad H3K4me3 peaks is associated with reduced expression of tumorsuppressor genes.
Conserved broad H3K4me3 suggests putative tumor suppressors
The strong enrichment of known tumor suppressors among genes with conserved broad H3K4me3 peaks (Supplementary Table 3) suggests that this epigenetic mark might be used to identify candidate tumor suppressors. We therefore tested this hypothesis in three tissue types: liver, lung and breast. We first defined putative candidate tumor suppressors for a given tissue type by requiring that (i) the genes had not been defined (q > 0.5) as tumor suppressors or oncogenes on the basis of mutation analysis of 8,200 tumor-normal pairs 2 ; (ii) their promoter H3K4me3 peak was wider than 4 kb in over 20% of ENCODE normal cell types; (iii) their promoter H3K4me3 peak was wider than 3 kb in the given tissue type; and (iv) their mRNA expression levels in the given tissue type were higher than the median level for all genes. This allowed us to identify 251, 393 and 539 putative candidate tumor suppressors in liver, lung and breast cancers, respectively ( Supplementary  Fig. 17) . In an initial analysis to characterize the function of these putative candidate tumor suppressors, we randomly selected 24 
npg
A r t i c l e s candidates (8 from each tissue type), further requiring that they had not been defined as tumor suppressors in the literature. We then assessed the effect of silencing these genes on cell proliferation. Knockdown of the known tumor suppressor PTEN had the expected effect on cell growth (Fig. 8) . Similarly, knockdown of the vast majority of the candidate tumor suppressors with conserved broad H3K4me3 peaks led to a significant (P < 0.05) increase in cell growth, whereas knockdown of ten randomly selected genes with sharp H3K4me3 peaks and comparable expression levels ( Fig. 8a and Supplementary Fig. 18 ) did not promote cell growth in A549 lung cancer cells. Similar effects of candidate gene silencing on cell growth were also observed in HepG2 liver cancer cells and MCF7 breast cancer cells (Fig. 8b,c) . Together, these results indicate that the expression of the vast majority of candidate tumor suppressors inhibits cancer cell growth.
DISCUSSION
We have uncovered the first epigenetic signature, namely broad H3K4me3, specifically enriched at tumor suppressors. Broad H3K4me3 peaks that are conserved across normal cells may mark a set of pan-cancer tumor suppressors, whereas cell type-specific broad H3K4me3 peaks are associated with cell identity genes, some of which might be cell type-specific tumor suppressors. Furthermore, widespread shortening of broad H3K4me3 peaks in cancers is strongly associated with repression of tumor suppressors. This observation suggests that, in addition to complete loss of a few tumor suppressors at the DNA level, cancer development may be supplemented by a collective reduction in the expression of dozens of tumor suppressors. Different from typical H3K4me3 peaks, broad H3K4me3 peaks are an indicator of increased transcription elongation and enhancer activity. Our analyses indicate that regulators of transcription elongation may control the broad H3K4me3 signature. Another possible regulator of broad H3K4me3 peaks is UpSET, which has been reported to prevent the spread of active chromatin marks in Drosophila melanogaster 39 . MM5, the human homolog of UpSET, was also reported to bind H3K4me3 downstream of TSSs 40 . Our MNase digestion-based H3K4me3 ChIP-seq data indicated that the nucleosome positioning for broad H3K4me3 peaks is fuzzier than that for sharp peaks (Supplementary Fig. 19 ). More work will be needed to fully understand the mechanisms governing broad H3K4me3 peaks.
Broad H3K4me3 peaks are distinct from other epigenetic features reported before. First, although broad H3K4me3 and super-enhancers are both wide epigenetic domains that are enriched for transcription factor binding sites and cell identity genes, they have different conservation patterns and functional implications. Broad H3K4me3 peaks are conserved across cell types and are uniquely enriched in tumor suppressors; in contrast, super-enhancers tend to be cell-type specific and associate with key cancer-specific oncogenes 14 . Second, DNA methylation valleys 41 or canyons 42 are extended regions of low methylation that are at least ten times larger than typical CpG islands; however, <50% of these overlap with broad H3K4me3 peaks. Third, recent studies reported expansion of dimethylation of histone H3 at lysine 4 (H3K4me2) in genes with tissue-specific expression 43 and H3K4me3 spreading in a subset of patients with autism 44 ; however, the functional implications of these events in cancer have not been established. Finally, while this work was under review, Benayoun et al. 45 reported that H3K4me3 peak breadth is linked to cell identity. Nevertheless, the major novelty of our work is the discovery of the association between pan-cancer tumor suppressors and conserved broad H3K4me3 peaks in normal cells. Furthermore, Benayoun et al. 45 indicated that H3K4me3 peak breadth was not correlated with gene expression. However, through careful reanalysis of the H3K4me3 raw data and simulation study from Benayoun et al., we conclude that the lack of correlation is largely due to inappropriate statistical methodology (Supplementary Fig. 20) .
Recent cancer genome sequencing has characterized a large number of non-uniformly distributed somatic mutations, with the differences in local mutation density exceeding up to fivefold 6 . The underlying mechanisms of mutational heterogeneity include alterations in DNA replication timing 4 and gene expression levels 6 . Therefore, to identify significantly mutated genes in cancers, a common practice is to correct for variation by using patient-specific and gene-specific 'background' mutation rates 6 . Our study suggests a new layer of 'foreground' information suggesting that genes with conserved broad H3K4me3 peaks (Supplementary Figure 8 Functional characterization of putative new tumor suppressors defined by conserved broad H3K4me3 peaks. (a-c) A549, HepG2 (b) and MCF7 (c) cells were transfected with the indicated small interfering RNAs (siRNAs), and cell proliferation was measured using the WST-1 assay. Error bars, s.d. calculated from three replicates. ***P < 0.001, **P < 0.01, *P < 0.05, compared to control siRNA in t tests. TPM, transcript number for a given gene per million total transcripts in each cell.
suppressors (Fig. 8) . Together, the broad H3K4me3 epigenetic signature provides mutation-independent information for the discovery and characterization of new tumor-suppressor genes. 2 . TUSON is a computational method that analyzes the patterns of mutation in tumors and predicts the likelihood that any individual gene functions as a tumor suppressor or oncogene. We ranked tumor suppressors by their TUSON prediction P values from the most to the least significant and used the top 500 genes (P < 0.01) as reference tumor suppressors throughout this study. We also used the same strategy to define the top 500 reference oncogenes.
URLs
ChIP-seq, MeDIP-seq and MRE-seq analyses. Sequencing reads were mapped to version hg19 of the human genome or to version mm9 of the mouse genome. The Dregion function in DANPOS 48 version 2.2.0 was used for read density calculation and peak calling. Briefly, we extended each read at the 3′ end to be 200 bp long and then calculated read density as the number of reads covering each base pair in the genome. For each data set, the total number of mapped reads was normalized to 25 million followed by quantile normalization. In step 1, we used a peak calling occupancy cutoff (Poisson P = 1 × 10 −8 ) to define seed peaks. In step 2, we used an extending occupancy cutoff (Poisson P = 1 × 10 −5 ) to extend the seed peak. If the occupancies at each nucleotide between seed peaks were all higher than the cutoff in step 2, then the seed peaks were merged into a single broad peak. In step 3, only neighboring seed peaks separated by <3 kb could be merged into a single broad peak. When the distance between two seed peaks is too great, even if there is considerable H3K4me3 signal between them, it is still possible that they are two independent peaks. Therefore, we added step 3 to require that only an extension shorter than 3 kb could be allowed. We used the broad-peak function in MACS2 for steps 1 and 2 and included the additional step 3 for a more stringent definition of broad peaks. Notably, using different extension lengths did not change our observations, for example, with broad and sharp peaks ( Supplementary  Fig. 21 ) or the association between broad H3K4me3 peaks and tumor suppressors ( Supplementary Fig. 22 ). The multimodal distribution of H3K4me3 peak sharpness was also not due to extension length but might be due to different statistical properties of H3K4me3 signals at different genes ( Supplementary  Fig. 23 ). We mapped each peak to a TSS using the GREAT algorithm, requiring the peak to be located within the region from −10 kb to +4 kb with respect to the TSS. We used the profile function in DANPOS version 2.2.0 to calculate the average read density flanking a group of TSSs or gene bodies. MEV version 4.5.0 was used to plot heat maps.
Microarray analysis. We downloaded Affymetrix array data from the ENCODE project website and Affymetrix U133 Plus 2.0 array data for CD4 + T cells from the Gene Expression Omnibus (GEO; accession codes available in Supplementary Table 1) . We then used the ReadAffy and RMA functions in the Affy R package to calculate the expression value for each gene.
RNA sequencing analysis.
For TCGA data sets, expression value (in TPM) for each gene in each sample were downloaded from the project website (see URLs). For other RNA-seq data, we downloaded raw reads from the GEO database (accession codes available in Supplementary Table 1) , used TopHat to map reads to the hg19 human reference genome, used the htseq-count function in HTSeq to calculate read counts for each gene and calculated gene expression (in fragments per kilobases per million, or FPKM) on the basis of the read counts. Gene expression values between samples were normalized using the normalizeQuantiles function in the limma R package.
Function enrichment analysis. We used DAVID for KEGG pathway analysis. Each pathway with a q value (Bonferroni corrected) smaller than 1 × 10 −3 in Figure 1 or 0.05 in the other figures was defined as significantly enriched. Enrichment levels for tumor suppressors, oncogenes and housekeeping genes were defined on the basis of Fisher's exact tests. Because gene number may affect P values (Supplementary Fig. 24 ), to make fair comparison between different gene sets, we always used the same number of top ranked genes for the Fisher's exact test.
Pol II pausing index calculation. We defined the pausing region as the region from 30 bp upstream to 300 bp downstream of the TSS and defined the elongation region as the region from 300 bp downstream of the TSS to 1 kb downstream of the TTS. We then calculated the pausing index as the pausing to elongation ratio of Pol II ChIP-seq read density. 
